Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 3OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 15Temozolomide 14Carmustine 6Lomustine 3Chemotherapy, Adjuvant 3Bevacizumab 3imetelstat 2Radiosurgery 2Radiation 2Immunohistochemistry 2Everolimus 2DNA Methylation 2vistusertib 1veliparib 1vatalanib 1temsirolimus 1sagopilone 1rubitecan 1palbociclib 1mercaptoundecahydrododecaborate 1marizomib 1lonafarnib 1fluciclovine F-18 1carmustine, poliferprosan 20 drug combination 1beta-D-glucosylisophosphoramide mustard 1azurin (50-77) 1Tamoxifen 1Re-Irradiation 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioblastoma × veliparib × Clear all
NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡